PMID- 35085735
OWN - NLM
STAT- MEDLINE
DCOM- 20220505
LR  - 20220505
IS  - 1569-8041 (Electronic)
IS  - 0923-7534 (Linking)
VI  - 33
IP  - 4
DP  - 2022 Apr
TI  - Concomitant type 2 diabetes mellitus (T2DM) in metastatic melanoma patients could 
      be related to lower level of LAG-3: a transcriptomic analysis of a retrospective 
      cohort.
PG  - 445-447
LID - S0923-7534(22)00016-3 [pii]
LID - 10.1016/j.annonc.2022.01.007 [doi]
FAU - Mallardo, D
AU  - Mallardo D
AD  - Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto 
      Nazionale Tumori IRCCS Fondazione 'G. Pascale', Naples, Italy.
FAU - Cortellini, A
AU  - Cortellini A
AD  - Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du 
      Cane Road, W120HS London, UK.
FAU - Capone, M
AU  - Capone M
AD  - Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto 
      Nazionale Tumori IRCCS Fondazione 'G. Pascale', Naples, Italy.
FAU - Madonna, G
AU  - Madonna G
AD  - Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto 
      Nazionale Tumori IRCCS Fondazione 'G. Pascale', Naples, Italy.
FAU - Pinato, D J
AU  - Pinato DJ
AD  - Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, Du 
      Cane Road, W120HS London, UK; Division of Oncology, Department of Translational 
      Medicine, University of Piemonte Orientale, Novara, Italy.
FAU - Warren, S
AU  - Warren S
AD  - NanoString Technologies, Seattle, USA.
FAU - Simeone, E
AU  - Simeone E
AD  - Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto 
      Nazionale Tumori IRCCS Fondazione 'G. Pascale', Naples, Italy.
FAU - Ascierto, P A
AU  - Ascierto PA
AD  - Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto 
      Nazionale Tumori IRCCS Fondazione 'G. Pascale', Naples, Italy. Electronic 
      address: paolo.ascierto@gmail.com.
LA  - eng
PT  - Letter
DEP - 20220125
PL  - England
TA  - Ann Oncol
JT  - Annals of oncology : official journal of the European Society for Medical 
      Oncology
JID - 9007735
SB  - IM
MH  - Cohort Studies
MH  - *Diabetes Mellitus, Type 2/complications/genetics
MH  - Humans
MH  - *Melanoma/complications/genetics
MH  - Retrospective Studies
MH  - Transcriptome
COIS- Disclosure AC received consulting fees from MSD, BMS, AstraZeneca, and Roche; and 
      speakers' fee from AstraZeneca, MSD, Novartis, and Astellas. DJP received lecture 
      fees from ViiV Healthcare, Bayer Healthcare, BMS, Roche, EISAI, and Falk 
      Foundation; travel expenses from BMS and Bayer Healthcare; consulting fees for 
      Mina Therapeutics, EISAI, Roche, DaVolterra, and Astra Zeneca; and research 
      funding (to institution) from MSD and BMS. SW is employee and stockholder in 
      NanoString Technologies. ES received honoraria from Bristol Myers Squibb, 
      Novartis, and Merck Sharp & Dohme. PAA has/had a consultant/advisory role for 
      Bristol Meyers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Merck 
      Serono, Pierre-Fabre, AstraZeneca, Sun Pharma, Sanofi, Idera, Sandoz, Immunocore, 
      4SC, Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, 
      Pfizer, OncoSec, Nouscom, Lunaphore, Seagen, and iTeos; received research funds 
      from Bristol Meyers Squibb, Roche-Genentech, Pfizer, and Sanofi. All other 
      authors have declared no conflicts of interest.
EDAT- 2022/01/28 06:00
MHDA- 2022/05/06 06:00
CRDT- 2022/01/27 20:12
PHST- 2021/11/19 00:00 [received]
PHST- 2022/01/11 00:00 [revised]
PHST- 2022/01/11 00:00 [accepted]
PHST- 2022/01/28 06:00 [pubmed]
PHST- 2022/05/06 06:00 [medline]
PHST- 2022/01/27 20:12 [entrez]
AID - S0923-7534(22)00016-3 [pii]
AID - 10.1016/j.annonc.2022.01.007 [doi]
PST - ppublish
SO  - Ann Oncol. 2022 Apr;33(4):445-447. doi: 10.1016/j.annonc.2022.01.007. Epub 2022 
      Jan 25.